Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 34, 2005 - Issue 5
Submit an article Journal homepage
744
Views
85
CrossRef citations to date
0
Altmetric
Original

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

M. C. Wick Departments of Rheumatology, Karolinska University Hospital, Solna
,
S. Ernestam Huddinge SE‐17176, Stockholm, Sweden
,
S. Lindblad Departments of Rheumatology, Karolinska University Hospital, Solna
,
J. Bratt Huddinge SE‐17176, Stockholm, Sweden
,
L. Klareskog Departments of Rheumatology, Karolinska University Hospital, Solna
&
R. F. van Vollenhoven Departments of Rheumatology, Karolinska University Hospital, SolnaCorrespondence[email protected]
Pages 353-358 | Received 07 Feb 2005, Accepted 27 May 2005, Published online: 12 Jul 2009

References

  • Maini R. N., St Clair E. W., Breedveld F., Furst D., Kalden J. R., Weisman M. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
  • Smith J. B., Haynes M. K. Rheumatoid arthritis—a molecular understanding. Ann Intern Med 2002; 136: 908–22
  • Olsen N. J., Stein C. M. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167–79
  • Calabrese L. H. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241–8
  • Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
  • Weinblatt M. E., Kremer J. M., Bankhurst A. D. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
  • Moreland L. W., Schiff M. H., Baumgartner S. W. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478–86
  • Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93
  • Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90
  • Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45
  • van de Putte L. B., Atkins C., Malaise M. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508–16
  • Keystone E. C., Kavanaugh A. F., Sharp J. T. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial. Arthritis Rheum 2004; 50: 1400–11
  • Van Vollenhoven R. F., Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003; 48: 1500–3
  • Van Vollenhoven R., Harju A., Brannemark S., Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195–8
  • Wagner C. L., Schantz A., Barnathan E., Olson A., Mascelli M. A., Ford J., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112: 37–53
  • Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long‐term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8
  • Hanauer S. B., Feagan B. G., Lichtenstein G. R., Mayer L. F., Schreiber S., Colombel J. F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9
  • Wagner C. L., St Clair E. W., Han C., Ford J., Schantz A., Maini R. N. Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study. Ann Rheum Dis 2002; 61((Suppl 1)), abstract
  • Hetland M. L., Unkerskov J., Ravn T., Friis M., Tarp U., Andersen L. S., et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005; 34: 40–4
  • Gutbrandsdottir S., Bliddal H., Petri A., Terslev L., Danneskiold‐Samsoe B., Bjornhard B., et al. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 385–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.